Trial Profile
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 25 Jan 2024
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary) ; Ruxolitinib
- Indications Myelofibrosis
- Focus Registrational; Therapeutic Use
- Acronyms PERSIST-2
- Sponsors Cell Therapeutics; CTI BioPharma
- 12 Dec 2023 Results (n=41) evaluating relationship between transfusion independence and reduction in BMF in MF patients treated with pacritinib, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results assessing transfusion response on survival in myelofibrosis patients treated with pacritinib, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results reporting rates of hematologic improvement in PLTs with pacritinib across PERSIST-2 and PAC203 clinical trial, presented at the 65th American Society of Hematology Annual Meeting and Exposition.